Over Cabrera

Over Cabrera is a notable inventor based in Carmel, IN (US), recognized for his contributions to the field of diabetes treatment. He holds two patents that focus on innovative methods and compounds aimed at improving the management of type 2 diabetes mellitus (T2DM).

Latest Patents

Cabrera's latest patents include a method of using a GIP/GLP-1 co-agonist for diabetes. This patent outlines methods for treating T2D using a novel dosing regimen of a GIP:GLP-1 peptide, which has a receptor agonist potency ratio ranging from about 2.5:1 to about 10:1 GIP to GLP-1. Additionally, he has developed compounds that exhibit activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These compounds are designed to have an extended duration of action and may be administered orally, making them potentially useful in treating T2DM and obesity.

Career Highlights

Cabrera is currently employed at Eli Lilly and Company, where he continues to advance research in diabetes treatment. His work has significantly contributed to the understanding and development of therapies that target metabolic disorders.

Collaborations

Some of Cabrera's notable coworkers include Jorge Alsina-Fernandez and Tamer Coskun, who collaborate with him in the pursuit of innovative solutions for diabetes management.

Conclusion

Over Cabrera's work exemplifies the impact of innovation in the medical field, particularly in the treatment of diabetes. His patents reflect a commitment to improving patient outcomes through advanced therapeutic methods and compounds.

Profile summary based on public USPTO records.